Literature DB >> 4018804

Susceptibility of different serovars of Chlamydia trachomatis to inactivation by normal human serum.

M F Osborn, A P Johnson, D Taylor-Robinson.   

Abstract

The ability of a panel of normal human serum samples to inactivate 12 strains of Chlamydia trachomatis, each of a different serovar, was investigated. A wide range of antichlamydial activity was observed, with survival rates of C trachomatis varying from less than 1% in some experiments to 100% in others. The strain specificity of the anti-chlamydial activity exhibited by individual serum samples was not, however, related to the antigenic cross reactivity between serovars demonstrable by microimmunofluorescence testing, which suggested that type specific antigens were not predominantly involved in the inactivation process.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4018804      PMCID: PMC1011821          DOI: 10.1136/sti.61.4.244

Source DB:  PubMed          Journal:  Genitourin Med        ISSN: 0266-4348


  9 in total

Review 1.  New knowledge of chlamydiae and the diseases they cause.

Authors:  J T Grayston; S Wang
Journal:  J Infect Dis       Date:  1975-07       Impact factor: 5.226

2.  Simplified serological test for antibodies to Chlamydia trachomatis.

Authors:  B J Thomas; P Reeve; J D Oriel
Journal:  J Clin Microbiol       Date:  1976-07       Impact factor: 5.948

3.  A study of inactivation of Chlamydia trachomatis by normal human serum.

Authors:  A P Johnson; M F Osborn; S Rowntree; B J Thomas; D Taylor-Robinson
Journal:  Br J Vener Dis       Date:  1983-12

Review 4.  The rôle of Chlamydia trachomatis in genital-tract and associated diseases.

Authors:  D Taylor-Robinson; B J Thomas
Journal:  J Clin Pathol       Date:  1980-03       Impact factor: 3.411

5.  Early detection of chlamydial inclusions combining the use of cycloheximide-treated McCoy cells and immunofluorescence staining.

Authors:  B J Thomas; R T Evans; G R Hutchinson; D Taylor-Robinson
Journal:  J Clin Microbiol       Date:  1977-09       Impact factor: 5.948

6.  Toxic effect of human polymorphonuclear leukocytes on Chlamydia trachomatis.

Authors:  E C Yong; S J Klebanoff; C C Kuo
Journal:  Infect Immun       Date:  1982-08       Impact factor: 3.441

7.  Development and evaluation of an enzyme-linked immunosorbent assay (ELISA), using chlamydial group antigen, to detect antibodies, to Chlamydia trachomatis.

Authors:  R T Evans; D Taylor-Robinson
Journal:  J Clin Pathol       Date:  1982-10       Impact factor: 3.411

8.  Polypeptide composition of Chlamydia trachomatis.

Authors:  S H Salari; M E Ward
Journal:  J Gen Microbiol       Date:  1981-04

9.  Analysis of the human serological response to proteins of Chlamydia trachomatis.

Authors:  W J Newhall; B Batteiger; R B Jones
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

  9 in total
  4 in total

1.  Early complement components enhance neutralization of Chlamydia trachomatis infectivity by human sera.

Authors:  J S Lin; L L Yan; Y Ho; P A Rice
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

2.  Comparison of a single-antigen microimmunofluorescence assay and inclusion fluorescent-antibody assay for detecting chlamydial antibodies and correlation of the results with neutralizing ability.

Authors:  E M Peterson; R Oda; P Tse; C Gastaldi; S C Stone; L M de la Maza
Journal:  J Clin Microbiol       Date:  1989-02       Impact factor: 5.948

3.  Complement and Chlamydia psittaci: Early Complement-Dependent Events Are Important for DC Migration and Protection During Mouse Lung Infection.

Authors:  Martin Kohn; Christian Lanfermann; Robert Laudeley; Silke Glage; Claudia Rheinheimer; Andreas Klos
Journal:  Front Immunol       Date:  2021-03-09       Impact factor: 7.561

Review 4.  An Ancient Molecular Arms Race: Chlamydia vs. Membrane Attack Complex/Perforin (MACPF) Domain Proteins.

Authors:  Gabrielle Keb; Kenneth A Fields
Journal:  Front Immunol       Date:  2020-07-14       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.